Peripartum cardiomyopathy (PPCM) is defined as heart failure that may develop toward the end of pregnancy or months after delivery without an identifiable cause. While prognosis has improved substantially over the past several years, women with peripartum cardiomyopathy are still at risk for adverse outcomes.
Most women (50-80%) will make a full recovery (LVEF >50%) within first 6 months. For prognostic purposes, an LVEF ≥30% usually means a full recovery of left ventricular function is likely, while LVEF <30% suggests a slow or incomplete recovery with respect to achieving full ventricular function. Black ancestry is associated with reduced likelihood of recovery. Due to increased recognition and improved treatment, mortality has improved from 30-50% in 1970’s to 1.3-16% in 2000’s.
BMJ: State of the Art Review: Peripartum cardiomyopathy (2019)
Peripartum Cardiomyopathy: JACC State-of-the-Art Review (2020)
Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association (2016)
Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy (2016)
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
‘Ten Commandments’ of the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association
Alliance for Innovation on Maternal Health: Consensus Bundle on Cardiac Conditions in Obstetrics
Please log in to ObGFirst to access the 2T US Atlas